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Viral proteins16 (HPV16) genome expresses six regulatory proteins (E1, E2, E4, E5, E6, and E7)
which regulate viral DNA replication, gene expression, and cell function. We expressed HPV16 E2, E4, E6, and
E7 from bacteria as GST fusion proteins and examined their possible functions in RNA splicing. Both HPV16
E2, a viral transactivator protein, and E6, a viral oncoprotein, inhibited splicing of pre-mRNAs containing an
intron with suboptimal splice sites, whereas HPV5 E2 did not. The N-terminal half and the hinge region of
HPV16 E2 as well as the N-terminal and central portions of HPV16 E6 are responsible for the suppression.
HPV16 E2 interacts with pre-mRNAs through its C-terminal DNA-binding domain. HPV16 E6 binds pre-
mRNAs via nuclear localization signal (NLS3) in its C-terminal half. Low-risk HPV6 E6, a cytoplasmic protein,
does not bind RNA. Notably, both HPV16 E2 and E6 selectively bind to the intron region of pre-mRNAs and
interact with a subset of cellular SR proteins. Together, these ﬁndings suggest that HPV16 E2 and E6 are RNA
binding proteins and might play roles in posttranscriptional regulation during virus infection.
Published by Elsevier Inc.IntroductionRNA splicing is an essential step in the control of viral and
mammalian gene expression. It occurs immediately after a nascent
primary message is transcribed and consists of a series of cascaded
biochemical reactions that take place in a spliceosome. Spliceosome-
mediated pre-mRNA splicing involves ﬁve small U RNAs (U1, U2, U4,
U5, and U6) and many splicing factors. The ﬁrst step in the accurate
recognition of intron splice sites involves interaction of the 5′ splice
site (5′ ss) with U1, of the branch site with U2, and of the 3′ splice site
(3′ ss) with U2AF (U2 auxiliary factor). These interactions are
modulated by many cellular splicing factors including SR proteins
(Graveley, 2000). SR proteins are a growing family of structurally
related and highly conserved cellular splicing factors that are
characterized by the presence of an RNA-recognition motif (RRM)
and RS dipeptides. A group of classical SR proteins contains extensive
phosphorylated RS domains and can be recognized by the monoclonal
antibody mAb104 (Zahler et al., 1993). SR proteins are essential
splicing factors that modulate the selection of a suboptimal splice site
(Zheng, 2004). Many of them have redundant functions.
Human papillomaviruses (HPVs), a group of small DNA tumor
viruses, usually infect keratinocytes of skin or epithelial cells ofmucosa
and cause benign warts or occasionally malignancies (Lowy andy Branch, Center for Cancer
8, Bethesda, MD 20892-1868,
ng).
nc.Howley, 2001; zur Hausen, 2002). Viral gene expression in infected
cells depends on cell differentiation and usually leads to the expression
of six nonstructural viral regulatory proteins (E1, E2, E4, E5, E6 and E7)
from early regions of the virus genome and two structural viral capsid
proteins (L1 and L2) from late regions of the genome. Expression of
each of these genes requires extensive RNA splicing. However, the
factors that determinewhen a speciﬁc splicing pathwaywill be used to
express a speciﬁc gene remain largely unexplored.
The papillomavirus E2 protein is a 42-kDa nuclear protein con-
taining two deﬁned functional domains that are relatively conserved
among all papillomaviruses. The N-terminal domain, consisting of
∼200 amino acid (aa) residues, is crucial for transcriptional activation,
whereas the C-terminal domain, consisting of ∼100 aa residues,
possesses the DNA binding and dimerization properties of the protein.
These two domains are linked by a hinge region that lacks a conserved
aa sequence and varies in length among papillomaviruses (Hegde,
2002). The hinge in epidermodysplasia verruciformis-associated HPV
E2 contains ∼200 aa residues and multiple RS dipeptide repeats, but
the hinge in anogenital HPV E2 is ∼40–80 aa residues and lacks RS
repeats (Sakai et al., 1996; Hegde, 2002). Besides its involvement in
papillomavirus DNA replication (Hughes and Romanos, 1993; Sakai
et al., 1996; Frattini and Laimins, 1994), E2 is also a transcriptional
activator or repressor that regulates the E6 promoter through four
consensus E2-binding sites (E2-BSs), ACC(N6)GGT (Androphy et al.,
1987; Hawley-Nelson et al., 1988; Sousa et al., 1990; Romanczuk et al.,
1990), upstream of the viral E6 promoter. However, E2 functions as a
repressor at steps after TBP or TFIID binding (Hou et al., 2000) and its
transcriptional repression occurs only in cells harboring integrated,
Table 1
Optimized conditions for expressing HPV–GST fusion proteins in E. colia
GST fusions IPTG (mM)b Induction at °C Induction time (h)
16E2 wt 0.7 18 20
16E2ΔC227 1 25 2
16E2ΔN220 0.5 18 20
16E2ΔN259 1 18 20
16E2ΔC260 1 25 2
16E2ΔN220+C260 1 25 2
16E6 wt 0.25 25 3
16E6 mtc 0.25 25 3
16E6ΔN41 0.7 25 2
16E6ΔN102 1 25 2
16E6ΔN102 mtd 1 25 2
16E6ΔC103 1 25 2
16E6ΔC42 1 25 2
16E6ΔN41+ΔC103 1 18 20
16E4 wt 1 25 2
16E7 wt 1 37 2
5E2 wt 0.7 18 20
6E6 wt 0.5 25 3
GST 1 37 2
a BL21 Codon Plus (DE3)-RP strain.
b Final concentration.
c Point mutations in both NLS1 and NLS3 motifs (Tao et al., 2003).
d Point mutations in NLS3 motif (Tao et al., 2003).
33S. Bodaghi et al. / Virology 386 (2009) 32–43but not episomal HPV16 DNA (Bechtold et al., 2003), raising a question
about how E2might function. In general, HPV16 E2 (16E2) by transient
transfection is toxic tomammalian cells and is usually under detection
level, suggesting other functions of E2 in the induction of cell toxicity.
The ﬁnding that HPV5 E2 (5E2) facilitates RNA splicing and interacts
with SR proteins (Lai et al.,1999) suggests that HPV E2might play a role
at post-transcriptional level. RNA transcription and splicing are
coupled processes and many transcription factors have unexpected
roles in this coupled network (Maniatis and Reed, 2002).
HPV E4 is expressed as an E1^E4 protein of 92 aa residues inwhich
the N-terminal 5 aa residues are derived from the E1ORF spliced to the
E4 ORF. The E4 proteinwhich is ∼10 kDa in size is themost abundantly
expressed HPV protein and accumulates in differentiating cells of the
upper epithelial layers. E4 expression collapses the cytokeratin
network (Doorbar et al., 1991) and mediates cell cycle arrest in G2
(Davy et al., 2002; Nakahara et al., 2002). The E1^E4 protein of HPV16
also binds to a DEAD-box containing RNA helicase, but the function of
this association remains unknown (Doorbar et al., 2000). Since DEAD-
box proteins regulate gene expression mostly at post-transcriptional
levels, this observation implies that HPV16 E1^E4might be involved in
functions other than its effect on cytokeratin.
HPV16 E6 (16E6) and E7 (16E7) are viral oncoproteins that
inactivate, respectively, cellular p53 and pRB, two tumor suppressor
proteins essential for cell cycle control. 16E6 is an ∼18 kDa nuclear
protein and is composed of 151 aa residues. 16E6 contains two
hypothetical zinc ﬁngers involved in zinc binding (Kanda et al., 1991)
and three nuclear localization signals (NLS) (Tao et al., 2003) as well as
a PDZ-binding site in the N-terminus (Kiyono et al., 1997; Lee et al.,
1997). Besides its ability to immortalize and transform cells and
induce p53 degradation, 16E6 is also functionally involved in the
regulation of gene transcription (Desaintes et al., 1992; Klingelhutz et
al., 1996) through interaction with other transcription factors and
coactivators (Patel et al., 1999; Ronco et al., 1998; Kumar et al., 2002;
Veldman et al., 2001; Veldman et al., 2003; Thomas and Chiang, 2005).
However, it remains to be determinedwhat part of 16E6 is responsible
for these protein–protein interactions because 16E6, like16E2, is
usually under detection level in cells after transient transfection. 16E7
is a nuclear protein with 98 aa residues in size. The N-terminal 37 aa
residues of 16E7 have been characterized as an important portion of
the protein that contributes to pRB binding and degradation as well as
cell transformation. Similar to 16E6, 16E7 also interacts with cellular
transcription factors and coactivators (Massimi et al., 1997; Avvaku-
mov et al., 2003; Bernat et al., 2003; Huang andMcCance, 2002). Many
of these interactions appear to involve the C-terminal half of 16E7, but
their biological relevance remains to be understood. In addition to the
protein–protein interactions of both 16E6 and 16E7, 16E6 has been
shown to be a DNA binding protein (Imai et al., 1989; Ristriani et al.,
2000; Ristriani et al., 2001; Nomine et al., 2003); the function of this
DNA binding also remains unknown.
We recently showed that GFP-16E6 fusion is a nuclear and
speciﬁcally, a nucleolar protein (Tao et al., 2003), and its nuclear or
nucleolar localization is controlled by its three NLSs. Since the nucleoli
are enriched with various small RNAs and NLS3 seems to strengthen,
rather than to promote, the nuclear localization of the protein, we
proposed that the major function of NLS3 might be to retain the
protein in the nucleus, perhaps through an interaction with a nucleic
acid (DNA or RNA) (Tao et al., 2003). Based on these observations and
difﬁculties to express detectable HPV16 E2 and E6 inmammalian cells,
we expressed E2, E4, E6 and E7 as GST-fusion proteins from individual
HPV16 ORFs in E. coli and analyzed their possible interactions with
RNAs and involvements in post-transcriptional regulation. We report
here that both 16E2 and 16E6 are RNA binding proteins. 16E2 binds
RNA through its characteristic DNA-binding domain and 16E6 binds
RNA via its C-terminal half. Perhaps most importantly, both 16E2 and
16E6 were found to suppress RNA splicing and to interact with
SR proteins.Results
Expression of HPV proteins as GST-fusion proteins in E. coli
Various expression conditions were used to efﬁciently express
each viral protein as a GST fusion in two bacteria strains, BL21(DE3)
pLysS and BL21 Codon Plus (DE3)-RP, a bacteria strain harboring
extra copies of tRNA genes that are rare in E. coli, but common in
humans. Optimized expression conditions were obtained empirically
for each protein and are summarized in Table 1. HPV16 E2 and E6, as
well as some of their truncated mutants, were difﬁcult proteins to
express in BL21(DE3)pLysS. When expressed in this bacteria strain at
room temperature or at 37 °C, they tended to form inclusion bodies
and were toxic to the bacteria. Especially when 16E2 was expressed,
the transformed bacteria had difﬁculty reaching the OD600 value
(0.6) required for the initiation of IPTG induction and frequently
collapsed during early exponential growth. However, 16E2, 16E6, and
some of their mutants were expressed relatively more efﬁciently,
with fewer inclusion bodies, in the BL21 Codon Plus (DE3)-RP strain.
Other proteins, such as E4 and E7 were relatively easy to express in
either bacteria strains at room temperature or at 37 °C with a few
hours of induction.
Effects of HPV16 E2, E4, E6 and E7 on RNA splicing
HPV16 E2-, E4-, E6- and E7-GST fusion proteins extracted to near
homogeneity (Fig. 1A) were examined for their possible role in RNA
splicing. We utilized an RNA substrate, HPV16 E6E7 pre-mRNA(Zheng
et al., 2004), containing an exon 2 that was short but had a U1 binding
site attached as a splicing enhancer (Fig. 1B). The viral fusion proteins
(at 0.1, 1.0 or 5.0 μg) (5 μg of semipuriﬁed GST fusions were equivalent
to approximately 500 ng of an expected pure viral fusion protein, see
Materials and Methods) were pre-mixed with HeLa or 293 nuclear
extracts (NE), followed by the addition of the RNA substrate to be
tested in a splicing condition. As shown in Fig. 1C, HPV16 E6E7 RNA
was spliced efﬁciently in the presence (lanes 2–4) or absence (lane 1)
of 0.1, 1.0 or 5 μg of GST, but its splicing efﬁciency was reduced in the
presence of 16E2- and 16E6-GST fusion proteins in a dose-dependent
manner, reaching up to 3-fold reduction at 5 μg (equal to only 4% of
total NE protein in a splicing reaction) (lanes 7 and 13), indicating that
the 16E2- and 16E6-GST fusions are suppressive. HPV16 E4- and E7-
GST fusions at 5 μg exhibited a smaller suppressive effect (less than 2-
Fig.1. Inhibitory effect of the GST-HPV16 E2, E4, E6, and E7 fusion proteins on HPV16 E6E7 pre-mRNA splicing. (A) SDS-PAGE analysis of puriﬁed GSTand GST-HPV16 E2, E4, E6 and E7
fusion proteins (markedwith ⁎). Five μl of GSTand each GST-fusion protein expressed in E. coliwas resolved on a 10% SDS-PAGE gel and stained with Coomassie blue. (B) The structure
of HPV16 E6E7 pre-mRNA. The nucleotide positions of the exons (boxes) and an intron (line) in the virus genome are indicated below the structure. The black box on the RNA 3′ end
indicates a U1 binding site attached as a splicing enhancer. (C) Effect of GST and the GST-HPV16 E2, E4, E6 and E7 fusion proteins on splicing of HPV16 E6E7 pre-mRNA. In vitro RNA
splicing reactions were performed in the presence or absence of 0.1,1.0, or 5.0 μg of each fusion protein for 2 h at 30 °C. The splicing products were analyzed by electrophoresis on a 6%
denaturing PAGE gel. The splicing efﬁciency (% spliced) of each reaction is shown at the bottom of the gel. The identities of the spliced products and splicing intermediates are shown
to the right of the gel. M, size markers.
Fig. 2. Suppression of BPV-1 late pre-mRNA splicing by HPV16 E2 and E6 with or without GST fusion. (A) Electrophoretic proﬁle of puriﬁed proteins without GST fusion. GST was
removed by digestion with PreScission protease, and the proteins were resolved on 4–12% SDS-PAGE gels stained with Coomassie Blue. (B) Structure of BPV-1 late pre-mRNA
containing an exonic splicing enhancer, SE1, in its exon 2. The sizes (nts) of two exons (boxes) and an intron (line) are indicated below the diagram. (C) Splicing gels. The RNA splicing
reactions were performed in the presence of 5 μg of 16E2 or 16E6 protein with (gel on the right) or without (gel on the left) GST fusion. Lanes 1 and 5 were unspliced pre-mRNA
controls. The splicing products were resolved on 6% denaturing PAGE gels and are identiﬁed between the two gels. Splicing inhibition (% inh.) by each protein is shown below each gel.
M, size markers.
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and 16E6 for the remaining studies in this report.
We further examined whether 16E2 and 16E6 with or without GST
(Fig. 2A) would inhibit the splicing of BPV-1 late pre-mRNA (Fig. 2B) as
described (Zheng et al., 1996). When mixed with HeLa NE, both 16E2
and 16E6 with or without GST suppressed the splicing. 16E2 and 16E6
lacking the GST fusion appeared to be more suppressive (Fig. 2C,
compare lanes 3 and 4 to lanes 7 and 8). The same was true for 16E2
and 16E6 when used for in vitro splicing of Drosophila doublesex (D.
dsx) exon 3 and exon 4 pre-mRNA (data not shown). Data indicate that
16E2 and 16E6 suppress splicing of all tested pre-mRNAs, with little
change by GST fusion.Fig. 3.Mapping of HPV16 E2 and E6 regions affecting splicing of BPV-1 late pre-mRNA. (A) S
coli (right) as well as their effect on RNA splicing. The numbers above each line diagram indi
GST-E2 fusion protein were resolved on a 10% SDS-PAGE gel stained with Coomassie blue,
indicated below. (B) Schematic diagram of full-length and truncated 16E6 (left) and their ex
panel A. (C, D) Inhibitory effects of the individual E2 (C) or E6 (D) fusion protein (5 μg) on RNA
unspliced pre-mRNA controls. See other details in Fig. 1C. Splicing inhibition (% inh.) by eacMapping of the HPV16 E2 and E6 regions involved in splicing suppression
of pre-mRNAs containing a suboptimal splice site
To deﬁne which regions of 16E2 and 16E6 are involved in
suppressing the splicing of pre-mRNAs, we constructed a series of
16E2 and 16E6 deletion mutants that were linked in frame to the C-
terminus of GST. Since three functional domains within the 365-aa
16E2 protein have been proposed and analyzed partially (Sakai et al.,
1996; Hegde and Androphy, 1998; Antson et al., 2000), the deletion
mutants of 16E2 were constructed based on the study by Sakai et al.
(Sakai et al., 1996) by deleting the C-terminal DNA binding domain,
the N-terminal transactivation domain, or both, with or withoutchematic diagrams of full-length and truncated 16E2 (left) and their expression from E.
cate the ﬁrst and last aa residue positions in each E2 protein. Expression proﬁles of each
with (+) or without (−) inhibitory effect of the individual E2 protein on RNA splicing
pression from E. coli (right) as well as their effect on RNA splicing. See other details in
splicing of BPV-1 late pre-mRNA (see Fig. 2B for RNA structure). Lane 1 in (C) or (D) was
h protein is shown below each gel.
36 S. Bodaghi et al. / Virology 386 (2009) 32–43deleting the hinge region (Fig. 3A). Because little is known about the
functional domains of 16E6, we made successive deletions beginning
at the N-terminus and progressing to the C-terminus of the 151-aa
protein, or vice versa (Fig. 3B). All mutants (mt) with deletions were
expressed as GST fusion proteins and examined for their effects on
splicing of BPV-1 pre-mRNA.
As shown in Fig. 3C, full-length wt 16E2 suppressed splicing (N2-
fold) of BPV-1 late pre-mRNA. Similarly, mt 16E2 without the C-
terminal DNA binding domain and with or without a hinge region
(E2ΔC227 and E2ΔC260) was also suppressive by ∼40–42%, suggest-
ing that the N-terminal transactivation domain is important for the
suppression. Deletion of the N-terminal transactivation domain of
16E2 (E2ΔN220 and E2ΔN259) was detrimental to the suppression,
further supporting this conclusion. However, the E2 hinge region
itself, when expressed as GST-fusion protein (E2ΔN220+ΔC260), also
inhibited the splicing by 44%, but when the hinge was combined with
the C-terminal DNA binding domain (E2ΔN220), the suppression was
only minimal (Figs. 3A and C), implying that the hinge in E2ΔN220
fusion may have a different conformation than the hinge alone in the
E2ΔN220+ΔC260 fusion.
E6 with a deletion of the N-terminal 41 aa residues (E6ΔN41) or of
the C-terminal 49 aa residues (E6ΔC103) was able to suppress BPV-1
RNA splicing by 46% or 34%, respectively (Fig. 3D), but the protein
without the central portion from aa 42 to 102 (E6ΔN102 and E6ΔC42)
had only a mild inhibitory effect (20% and 27%, respectively),
indicating that the central region (aa 42–102) of 16E6 is more
suppressive. The ﬁnding of that the fusion protein with the central
region of 16E6 alone (E6ΔN41+ΔC103) was even more suppressive
(65%) than any other E6 fusions, including wt full-length E6 (38%)
(Figs. 3B and D), supports this conclusion.
To conﬁrm our mapping results, 16E2, 16E6, and the mutants that
retained the ability to suppress splicing were further examined on
splicing of HPV16 E6E7 pre-mRNA. The results for individual proteinsFig. 4. Effect of full-length or truncated HPV16 E2 without a GST tag and full-length HPV5 E2
and 5E2with GST (lane 6). All proteins were digested at 4 °C overnight with PreScission prote
staining. (B) Effect of full-length and truncated 16E2 proteins and full-length 5E2 protein
denaturing PAGE gel. Lane 2 in (B) was unspliced pre-mRNA controls. (C, D) Effect of GST-5E
products and splicing intermediates are shown on the right of the gel. See other details in Fwere very similar to the results for BPV-1 (data not shown). Similar
results were also obtained for splicing of D. dsx pre-mRNA (data not
shown).We also tested the suppressive proteins without GST (Fig. 4A),
and found that all wt and mt forms of 16E2 (Fig. 4B, lanes 5–7) and
16E6 tested (data not shown) were suppressive. However, 5E2 with
(lane 1, Figs. 4C and D) or without GST (lane 4, Fig. 4B), which was
reported to enhance RNA splicing in vivo (Lai et al., 1999), did not have
much suppressive activity.
Although both 16E2 and 16E6 inhibited the splicing of all three
pre-mRNAs (HPV16 E6E7, BPV-1ate, and D. dsx) bearing a suboptimal
intron, these proteins and most of their suppressive mutants showed
only a little effect on human β-globin pre-mRNA which contains a
strong intron 1 (data not shown), suggesting that the observed
suppressive effects of 16E2 and 16E6 on RNA splicing are dependent
upon the features of the pre-mRNAs. One of the 16E6 mutants,
16E6ΔN41+ΔC103, did have some suppressive effect (∼30%) on β-
globin pre-mRNA (Data not shown); this mutant was also the
strongest inhibitor of splicing for all of the other pre-mRNAs.
HPV16 E2 and E6 are RNA-binding proteins and contain a protein–RNA
interaction domain in their C-terminal regions
To understand how 16E2 and 16E6 affect RNA splicing, we carried
out a series of protein–RNA interaction experiments.We hypothesized
that 16E2 and 16E6 could affect RNA splicing by binding to the RNA.
Although both 16E2 and 16E6 have been demonstrated to be DNA-
binding proteins (Thain et al., 1997; Ristriani et al., 2000; Ristriani et
al., 2001), it was not knownwhether the two proteins could also bind
to RNAs. Since both 16E2 and 16E6 induced degradation of HPV16
E6E7 pre-mRNA in our gel-shift conditions (data not shown), we
therefore analyzed full-length 16E2, 16E6, and their truncated
mutants for RNA-binding (Figs. 5A and B) by UV cross-linking and
RNase digestion assays. In these assays, a protein that binds to a 32P-on splicing of pre-mRNAs. (A) Puriﬁed wt and truncated 16E2 (lanes 2–4) without GST
ase, and each proteinwas resolved on a 4–20% SDS-PAGE gel followed by Coomassie blue
without GST on 16E6E7 RNA splicing. The splicing products were analyzed on a 6%
2 on splicing of 16E6E7 (C) and BPV-1 late (D) pre-mRNAs. The identities of the spliced
ig. 2C. Splicing inhibition (% inh.) by each protein is shown below each gel.
Fig. 5.Mapping of HPV16 E2 and E6 domains involved in protein–RNA interaction using UV cross-linking and RNase digestion. (A, B) Diagrams of various 16E2 (A) and 16E6 (B) fusions
and their binding activities to HPV16 E6E7 pre-mRNA. (C) 16E2 RNA-binding gel. (D) 16E6 RNA-binding gel. Each protein (see protein proﬁles in Figs. 3A and B) was incubated ﬁrst
with α-32P-labeled HPV16 E6E7 pre-mRNAs (see RNA structures in Fig. 1B) before UV cross-linking and RNase A/T1 digestion. The protein–RNA complexes were then heated to 95 °C
for 10 min in 2× SDS sample buffer and resolved on 10% [left gel in (C) and gel in (D)] or 4–12% gradient [right gel in (C)] SDS-PAGE gels. One representative experiment of ﬁve is
shown. Arrows, non-speciﬁc (NS) binding; ⁎, speciﬁc binding.
37S. Bodaghi et al. / Virology 386 (2009) 32–43labeled RNA in close contact can be covalently crosslinked to the RNA
by UV irradiation and consequently prevents the bound RNA region
from RNase digestion. As shown in Figs. 5C and D, both full-length
16E2 and 16E6 fusion proteins exhibited RNA-binding activities for
HPV16 E6E7 pre-mRNA (lane 1 in C and D), whereas GST itself did not
(lanes 7 and 10 in C and lane 7 in D). All of the fusion proteins and GST
itself sometimes displayed a non-speciﬁc binding band (arrows in C
and D) which overlaps the position of full-length 16E2 (lane 1 in C).
However, a wt, full-length E2-RNA binding reaction gave a much
higher density band at this position, representing the binding of 16E2
to the RNA (lane 1 in C). In separate experiments using a gradient gel,
the 16E2-speciﬁc band could be separated from the non-speciﬁc band
(lane 8 in C) which was not a problem for the much smaller, wt 16E6
fusion protein (lane 1 in D). Thus, we conclude that both 16E2 and
16E6 are RNA-binding proteins.
Fig. 5C also shows that the truncated 16E2 fusion proteins retaining
the N-terminal transactivation domainwith or without a hinge region
(E2ΔC227 and E2ΔC260, lanes 2 and 5) exhibited no RNA-binding
activity, whereas the truncated 16E2 proteins containing the C-
terminal DNA-binding domain with (E2ΔN220, lane 3) or without
(E2ΔN259, lanes 4 and 9) the hinge region bound to HPV16 E6E7 pre-
mRNA. The hinge region itself (lane 6) had no RNA-binding activity
and neither of its extended version [20 aa more on both ends (Antson
et al., 2000)] could render such binding (data not shown).
Fig. 5D shows mapping analysis of 16E6 to identify the region in
16E6 responsible for the RNA binding, using all six 16E6 fusions. Threeof the six proteins, wt E6, E6ΔN41, and E6ΔN102, bound to RNA (lanes
1–3), but the other three fusion proteins, E6ΔC103, E6ΔC42, and
E6ΔN41+ΔC103, did not (lanes 4–6). The truncated 16E6 without the
N-terminal 102 aa residues retained the RNA binding activity
(E6ΔN102, lane 3), but a 16E6 mutant containing only the N-terminal
102 aa residues was deﬁcient in the binding (E6ΔC103, lane 4),
indicating that the C-terminal 48 aa residues of 16E6 is responsible for
the protein–RNA interaction.
In addition to their binding to HPV16 E6E7 pre-mRNA, both HPV16
E2 and E6 were also shown to bind BPV-1 late and human β-globin
pre-mRNAs in separate experiments (data not shown).
A NLS3 sequence motif in the C-terminus of HPV16 E6 is responsible for
protein–RNA interactions
The C-terminus of 16E6 contains a NLS, NLS3. NLS3 is unable to
convert the cytoplasmic E6 of low-risk HPV6 (6E6) into a nuclear
protein, but appears to strengthen nuclear localization of 16E6; we
have therefore proposed that the major function of NLS3 might be to
retain the protein in the nucleus, probably through a nucleic acid (DNA
or RNA) interaction (Tao et al., 2003). To examine whether the RNA
binding of 16E6 could be a function of NLS3, the C-terminal 48-aa
region with or without an NLS3 mutation (Fig. 6A) (Tao et al., 2003)
was examined for its ability to bind RNA. The C-terminal region
containing a mutant NLS3 lost its RNA binding activity (compare
E6ΔN102 in lanes 1 and 3 to E6ΔN102 mt in lane 2, Fig. 6B), indicating
Fig. 6. High-risk HPV16 E6 containing NLS3 mutation and low-risk HPV6 E6 lack RNA
binding activity. (A) Diagrams of wt or mt 16E6 fusion proteins with (black boxes) or
without (crossed black boxes) a wt NLS3 and their RNA binding activities in comparison
with 6E6. 6E6 has a non-functional NLS3-like structure, with few aa residue variations,
in the region corresponding to 16E6 NLS3 (Tao et al., 2003) and is a cytoplasmic protein.
(B) A 16E6 NLS3 motif is responsible for protein–RNA interaction. GST-16E6 fusion
protein with or without mutations in both NLS1 and NLS3 (Tao et al., 2003) and a
truncated 16E6ΔN102 fusion protein with or without mutations in its NLS3 motif were
examined for their binding and UV cross-linking to 16E6E7 pre-mRNA. (C) HPV6 E6 is
not an RNA binding protein. GST-6E6 was compared with wt or truncated 16E6 for its
RNA binding. HPV16 E6E7 pre-mRNA (see Fig. 1B) was used for each assay. One
representative experiment of three is shown in (B) and (C). Arrows, non-speciﬁc (NS)
binding; ⁎, speciﬁc binding.
Fig. 7. Intron regions of HPV16 E6E7 pre-mRNA have high afﬁnity for binding of a
truncated 16E2 or 16E6 fusion protein. (A) Schematic diagrams of HPV16 E6E7 pre-
mRNAs used for in vitro protein binding and UV cross-linking. On the top of the panel is
a diagram of the HPV16 E6E7 pre-mRNA including exon 1, intron 1, and exon 2, showing
various 5′ ss and 3′ ss. The numbers at each RNA end are the nt positions in the virus
genome. (B, C) Mapping of HPV16 E6E7 RNA regions that interact with a truncated
16E2ΔN259 (B) or 16E6ΔN102 (C) fusion protein. See Fig. 5 for other details. Protein–
RNA complexes from each reaction were resolved on a 10% SDS-PAGE gel. The letters at
the tops of each gel indicate the individual RNA substrate in (A) used for the binding and
UV cross-linking. One representative experiment of two is shown. NS arrows, non-
speciﬁc binding; S arrowheads, speciﬁc RNA–protein interactions.
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interaction. This result was further conﬁrmed in the context of wt,
full-length 16E6 fusion protein with or without mutations in both
NLS1 and NLS3 (compare lane 4 to lane 5, Fig. 6B). Since the N-
terminal region containing wt NLS1 (Tao et al., 2003) (see E6ΔC42 in
Fig. 5D, lane 5) had no RNA binding activity, the loss of the RNA
binding activity in the full-length 16E6 with mutations in both the
NLS1 and NLS3 had to be a result solely from mutation in the NLS3.
We also compared HPV16 E6 with the low-risk 6E6 for their ability
to bind RNA since the 6E6 is a cytoplasmic protein and its
corresponding region to the 16E6 NLS3 has variations in aa residues.
Data in Fig. 6C shows, as expected, that the low-risk cytoplasmic 6E6
lacked this RNA-binding activity (compare lane 4 to lane 2).
HPV16 E2 and E6 preferentially interact with the intron region of
a pre-mRNA
We next wished to identify the RNA sequences targeted by the C-
terminal binding domain of 16E2 and the NLS3 of 16E6. HPV16 E6E7
pre-mRNA was chosen because both 16E2 and 16E6 bind to this RNA
which is available for the binding during virus infection. Various sizes
of 16E6E7 pre-mRNA transcribed in vitro and uniformly labeled with
32P (Fig. 7A) were utilized for the mapping in the presence of the16E2ΔN259 (Fig. 7B) or 16E6ΔN102 (Fig. 7C) fusions. The 16E2ΔN259
and 16E6ΔN102 fusions were selected for the assay because they are
smallest proteins to confer the same amount of RNA binding activity
as their full-length counterparts (Figs. 5C and D). As shown in Fig. 7,
almost all the RNA fragments used for the assay, except for RNA C,
interacted efﬁciently with the two proteins. RNA C is composed solely
of the exon 1 region of the 16E6E7 pre-mRNA and exhibited no
binding to 16E2ΔN259 (Fig. 7B) or 2–3-fold less binding afﬁnity to
16E6ΔN102 (Fig. 7C) than that of the other RNAs. All of the RNAs that
did bind (A, B, D, E, and F) contained all or part of intron 1, and RNA E
and RNA F contained only intron 1.We therefore concluded that intron
1 of 16E6E7 pre-mRNA is likely to be the region interacting with the
16E2ΔN259 and 16E6ΔN102 fusions.
Since 16E6E7 pre-mRNA contains three alternative 3′ splice sites in
intron 1, the size of intron 1 in the pre-mRNA would vary depending
on which 3′ splice site is selected for the splicing. Thus, the exon
39S. Bodaghi et al. / Virology 386 (2009) 32–43sequences upstream of an alternative 3′ splice site could be part of
intron 1. If the intron region binds 16E2ΔN259 and 16E6ΔN102, the
part of the intron upstream of an alternative 3′ splice site should have
the same binding afﬁnity. This prediction was conﬁrmed using RNAs
G, H, and I and further veriﬁed using RNA J, which was transcribed
from an E6E7 cDNA lacking intron 1 from nt 227 to nt 408, but
remaining the entire portion of RNA G (Figs. 7B and C). Altogether,
these data indicate that the entire intron 1 region of 16E6E7 pre-
mRNA contains multiple sequence motifs that interact directly with
both 16E2ΔN259 and 16E6ΔN102 and prevent the bound RNA from
RNase digestion.
HPV16 E2 and E6 interact with multiple cellular SR proteins
To further explore how 16E2 and 16E6 could suppress pre-mRNA
splicing by interacting with RNA, we investigated protein–protein
interactions using a GST pull-down assay, under the assumption that
the two viral proteins might interfere with the cellular splicing
machinery in addition to their RNA binding activities. Full-length and
several truncated 16E2 fusions were chosen for GST pull-down assays
using HeLa NE. The proteins that were pulled downwere examined by
Western blotting using mAb104, a monoclonal anti-SR protein
antibody that recognizes a phosphoepitope in the RS domain of all
classical SR proteins (Zahler et al., 1993). As shown in Fig. 8A, the full-
length 16E2 was found to interact with SRp30, SRp40 and SRp75 (lane
3), but only weakly with SRp55. The truncated 16E2ΔN259 which
binds RNA but has little effect on RNA splicing interacted with SRp30,
SRp40 and very little SRp55, but not SRp75 (lane 4). A protein with aFig. 8. HPV16 E2 and E6 fusion proteins interact with SR proteins. Full-length or truncated
immobilized on glutathione Sepharose 4B beads inmicrospin column and then incubated ove
on a 4–12% SDS-PAGE gel, transferred onto a nitrocellulose membrane, and blotted with mAb
(A) and in lane 3 (5.8 μg or ∼5% of the input) in (B). See E2 and E6 protein diagrams in Figs. 3
recognized by mAb104. One representative experiment of three is shown. (C) An NLS3 mot
Western blotting using mAb104. Lanes 3–7 in (C) also show some background staining for ea
size markers (lane 2 in A–C).size little larger than SRp75 that could be stained by mAb104 but was
absent at the same position from NE (compare lane 4 to lane 1)
appeared to be non-speciﬁc. GST (lane 6) and the E2ΔN220+ΔC260
fusion containing the E2 hinge region only (lane 5) did not interact
with any SR protein in the assay. Several other forms of truncated
16E2, including E2ΔC227 and E2ΔC260, also showed no SR protein
interaction (data not shown). These data suggest that the 16E2-SR
protein interaction domain (s) is distributed most likely across the C-
terminus of the protein.
We also examined full-length 16E6 and two truncated 16E6
fusions,16E6ΔN102 and 16E6ΔN41+ΔC103, for SR protein interactions
in GST pull-down assays using HeLa NE. 16E6ΔN102 and 16E6ΔN41+
ΔC103 were chosen because 16E6ΔN102 binds RNA, but has little
effect on RNA splicing, and 16E6ΔN41+ΔC103 does not bind RNA, but
suppresses RNA splicing. As shown in Fig. 8B, wt 16E6 interacted with
SRp30, SRp55, and SRp75 (lane 4). 16E6ΔN102 interacted weakly with
SRp30, SRp40, and SRp55, but not SRp75 (lanes 5 and 7). A protein
with a size little smaller than SRp40 in the 16E6 pull-downs (compare
lane 4 to lane 3) or a little larger than SRp75 in the 16E6ΔN102 pull-
downs (compare lanes 5 and 7 to lane 3) that could be stained by
mAb104 but was absent at the corresponding positions from NE
appeared to be non-speciﬁc. In contrast, 16E6ΔN41+ΔC103 interacted
much less with SRp30 and SRp75 (lane 1). Thus, as with 16E2, the C-
terminus of 16E6 contains most of the SR protein interaction domains.
To identify which portion of the C-terminus of 16E6 interacts with
SR proteins, we compared the SR protein interactions of 16E6ΔN102
and 16E6ΔN102 mt. 16E6ΔN102 mt differs from 16E6ΔN102 by
mutation of ﬁve aa residues in its NLS3motif (see NLS3mutations, Fig.16E2 (A) or 16E6 (B) fusions as well as GST protein freshly expressed from E. coli were
rnight at 4 °Cwith HeLa NE. After extensivewashes, the captured proteins were resolved
104. HeLa NE was loaded as an SR protein control in lane 1 (2.5 μg or ∼2% of the input) in
A and B. Shown on the left in each panel are four major SR proteins in HeLa NE that are
if in HPV16 E6 interacts with SR proteins. Proteins in the pull-downs were analyzed by
ch input fusion protein. One representative experiment of two is shown. M, pre-staining
40 S. Bodaghi et al. / Virology 386 (2009) 32–436A). The introduction of point mutations in the NLS3 motif disrupted
RNA binding (Fig. 6B) and was detrimental to the protein–protein
interaction (Fig. 8C, compare lane 3 to lane 5). Despite of some
background staining of the input fusion proteins, Fig. 8C also shows
that the N-terminal 41 aa residues of 16E6 had no activity for binding
SR proteins (lanes 4 and 7). Therefore, the C-terminal NLS3 of 16E6
that binds RNA also binds SR proteins.
Discussion
In this study, we have demonstrated that both 16E2 and 16E6
proteins inhibit splicing, and this inhibition of RNA splicing may be
associated with their RNA and protein–protein interactions. We have
also demonstrated that in both 16E2 and 16E6, suppression of RNA
splicing and interaction directly with RNA are two separate
functions that are performed by different domains: the N-terminal
half of each protein participates in the suppression of RNA splicing,
and the C-terminal half contributes to RNA binding (Fig. 9), despite
the fact that the C-terminal half does not contain any well
characterized RNA recognition motifs (Burd and Dreyfuss, 1994).
16E2 and 16E6 must be in close contact directly with the bound
RNAs and therefore could be covalently cross-linked to the bound
RNAs to prevent from RNase digestion. Several reports have
indicated that NLS motifs overlap DNA- or RNA-binding domains
in nuclear acid-binding proteins, and zinc ﬁngers in these proteins
are also possible RNA-binding motifs (LaCasse and Lefebvre, 1995).
HPV16 E6 is known to contain these structures (Tao et al., 2003), but
they have not been identiﬁed in the 16E2 protein. More importantly,
we have demonstrated that both 16E2 and 16E6 interact with a
subset of classical SR proteins, cellular splicing factors that areFig. 9. Functional domains of HPV16 E2 and E6 involved in RNA binding, RNA splicing, and S
HPV16 E2 and E6might interfere with SR protein-mediated intron removal through interactinpivotal components of the cellular splicing machinery. Unlike 5E2,
which contains multiple RS dipeptide repeats in a long, 200-aa hinge
region and interacts with SR proteins and other splicing factors, such
as SRp30 (ASF/SF2 and SC35), U1-70K, and U5-100K, through its RS
repeats (Lai et al., 1999), 16E2 has a short, 40-aa hinge (Sakai et al.,
1996) and lacks repeated RS sequences. 16E6 lacks all of those
structures. Although 5E2 has been suggested to facilitate RNA splicing
in vivo of CAT pre-mRNAs containing a β-globin intron (Lai et al.,
1999), we were unable to observe this activity in splicing of any pre-
mRNAs examined in our in vitro assays.
Functional analysis of each protein domain showed that the region
of the C-terminus with RNA binding activity overlaps with the region
responsible for SR protein interactions in both 16E2 and 16E6 (Figs. 9A
and B), as exempliﬁed by the NLS3 motif of 16E6. These overlapping
functions are not necessarily associated with the suppressive effects of
16E2 and 16E6 on RNA splicing, since truncated proteins containing
the C-terminal portion alone had no signiﬁcant effect on RNA splicing,
yet retained interactions with RNA and weakly with a subset of SR
proteins. However, that only the wt, full-length 16E2 or 16E6, but not
the truncated ones, were able to interact strongly with SRp75 suggests
that another region of 16E2 or 16E6 or conformational structures of
these two proteins might interact with SRp75 to mediate splicing
suppression. Together with the ﬁnding that both 16E2 and 16E6
preferentially bind to a pre-mRNA intron, the interactions of 16E2 and
16E6 with RNA and SRp75 may affect RNA splicing by interfering
recruitment and cross-talk of the splicing machinery over the intron
during RNA splicing (Fig. 9C). It has been known that binding of SR
proteins to an intronic region negatively regulates RNA splicing
(Kanopka et al., 1996) and many intronic elements are regulatory
elements in RNA splicing (Ladd and Cooper, 2002).R protein interactions. (A) HPV16 E2. (B) HPV16 E6. (C) A proposed model showing how
gwith SR proteins or other unknown factors and/or with an intron region of pre-mRNA.
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involved in 16E2- and 16E6-mediated splicing suppression. For
example, several of our truncated proteins with C-terminal deletions,
such as 16E2ΔN220+ΔC260, 16E2ΔC260 and 16E6ΔC103, had no
activity in binding of RNAs or classical SR proteins, but suppressed RNA
splicing. How these proteins block RNA splicing remains unknown.
However, it is important to note that in addition to interact with SR
proteins, HPV5 E2 is also capable to interact with other splicing
components, such as U1-70K and U5-100K (Lai et al., 1999). Since the
spliceosome comprises up to 150 different proteins (Zhou et al., 2002)
and themAb104 in our pull-downwestern blotting assays detects only
a subset of the classical SR proteins (Zahler et al.,1993; Graveley, 2000).
It is possible that these truncated proteins might interact with other
unknown cellular factors to disrupt functions mediated by the normal
splicing machinery.
Nevertheless, both wt 16E2 and wt 16E6 appeared to inhibit
splicing of all 3 pre-mRNAs containing a suboptimal intron in our
assays (16E6E7, BPV-1 late, and D. dsx), but had very little effect on
splicing of a human β-globin pre-mRNA, which contains an optimal
intron. The difference in RNA splicing among these pre-mRNAs could
therefore be due to the intrinsic structures of the pre-mRNAs. A pre-
mRNA containing a suboptimal intron or weak splice sites would not
be spliced efﬁciently in the absence of an exonic splicing enhancer
that is necessary, through interactionwith SR proteins, for recruitment
of U2AF to a suboptimal 3′ splice site. In contrast, splicing of a pre-
mRNA containing an optimal intron or strong splice sites usually does
not rely on an exonic splicing enhancer (Zheng et al., 2000; Zheng,
2004), and the 3′ splice site itself in this type of pre-mRNA is strong
enough for U2AF and U2 interaction. Therefore, the intrinsic structure
of a pre-mRNA may determine the consequences of the interactions
among the mRNA, 16E2, 16E6, and SR proteins, as characterized in the
present study.
However, these ﬁndings leave many questions to be addressed:
First, how do the protein–RNA and protein–protein interactions take
place in cells and if so, in what circumstances? Since RNAs are bound
with all kinds of cellular RNA-binding proteins along transcription in
progression, 16E2 and 16E6 must be in a competitive position for the
binding of their targeted RNAs during HPV infection. Second, are the
RNA and SR protein binding of 16E2 and 16E6 biologically signiﬁcant
in the virus life cycle and in viral oncogenesis? Unfortunately, many
attempts to detect the RNA binding and SR protein interactions of
16E2 and 16E6 in vivo were unsuccessful due to our difﬁculties with
expressing a detectable level of either 16E2 or 16E6 from mammalian
expression vectors in transient transfection assays or in the estab-
lished 16E2 or inducible 16E2 stable cell lines. Nevertheless, the
ﬁndings that both 16E2 and 16E6 are RNA binding proteins, interact
with cellular splicing factor SR proteins, and inhibit RNA splicing of
pre-mRNAs with a suboptimal intron provides compelling evidence
that some HPV regulatory proteins may also regulate gene expression
at posttranscriptional level.
Materials and methods
Construction of expression vectors
ORFs of E2 (nt 2756 to 3853), E4 (nt 865–880/3358 to 3620), E6 (nt
104 to 559) and E7 (nt 562 to 858) were ampliﬁed from pBR322-HPV
16R DNA (a gift from Dr. E.-M. de Villiers and H. zur Hausen) by
individual PCRs. Each was then cloned in frame into the C terminus of
GST at the EcoRI and XhoI sites of the polylinker region of the
expression vector pGEX-6P-1 (Amersham Pharmacia, Piscataway, NJ),
producing GST-E2, E4, E6 and E7 as individual GST fusion genes in
plasmid pSB-1, pSB-2, pSB-3 and pSB-4, respectively. The same cloning
strategy was used to create the following plasmids to express the
truncated E2 and E6 fusion proteins described in Figs. 3A and B:
plasmid pSB-5 for 16E2ΔC227 with a C terminal deletion from aa 227to 365, plasmid pSB-6 for 16E2ΔN220 with an N-terminal deletion
from aa 1 to 220, plasmid pSB-7 for 16E2ΔN259 with an N-terminal
deletion from aa 1 to 259, plasmid pSB-8 for 16E2ΔC260 with a C-
terminal deletion from aa 260 to 365, plasmid pSB-9 for 16E2ΔN220+
ΔC260 with both an N-terminal deletion from aa 1 to 220 and a C-
terminal deletion from aa 260 to 365 (thus, the fusion protein
expressed from plasmid pSB-9 has only the 16E2 hinge [40 aa] (Sakai
et al., 1996)), plasmid pSB-10 for 16 E6ΔN41 with an N-terminal
deletion from aa 1 to 41, plasmid pSB-11 for 16E6ΔN102 with an N-
terminal deletion from aa 1 to 102, plasmid pSB-12 for 16E6ΔC103
with a C-terminal deletion from aa 103 to 151, plasmid pSB-13 for
16E6ΔC42 with a C-terminal deletion from aa 42 to 151 and plasmid
pST-14 for 16E6ΔN41+ΔC103 with both an N-terminal deletion from
aa 1 to 41 and a C-terminal deletion from aa 103 to 151 (thus, the
fusion protein expressed from pSB-14 contains only the central part
[from aa 42 to 102] of E6). To express 16E6 with mutations in the NLS3
motif, two plasmids derived from plasmid pTMF45 (Tao et al., 2003)
were constructed: plasmid pSB-16 constructed encodes a full-length
E6 GST fusion with mutations in both the NLS1 and NLS3 motifs,
plasmid pSB-17 constructed as described for pSB-11 encodes a
16E6ΔN102 fusion with mutations in the NLS3 motif and the protein
expressed from this plasmidwas designated 16E6ΔN102mt. The same
strategywas also used to construct plasmids to express wild-type (wt)
HPV 5E2-GST and HPV6b E6-GST fusions; plasmid pSB-15 for 5E2
expression originated from plasmid pSP5E2 (a gift from Dr. Tarn) (Lai
et al., 1999) and plasmid pSB-20 for HPV6b E6 (6E6) expression was
derived from plasmid pZMZ66-1 (Tao et al., 2003).
Preparation of DNA templates and in vitro transcription
Various DNA templates were prepared for in vitro RNA transcrip-
tion. The transcribed RNAs were then used for in vitro RNA splicing or
RNA–protein interaction. To generate various pre-mRNAs for in vitro
RNA splicing, four different DNA templates were prepared: HPV16 E6
DNA templates were generated from pBR322-HPV16R by PCR with a
chimeric 5′ primer T7-HPV16 Pr107 (oZMZ 208, 5′-TAATACGA-
CTCACTATAGGGA/TTTCAGGACCCACAGGAGCGA-3′) combined with
an antisense 3′ primer with a 5′ end at nt 477 (oZMZ 219, 5′-
GTACTCACCCC/AATCTTTGCTTTTTGTCC-3′); BPV-1 late gene DNA
templates were generated by PCR from plasmid pZMZ19-1 (Zheng et
al., 1996) with a chimeric 5′ primer T7-BPV-1 Pr7276 (oFD 127, 5′-
TAATACGACTCACTATAGGGA/GCGCCTGGCACCGAATCC-3′) combined
with an antisense primer (oZMZ 84, 5′-GGCTGGGCTGGCTCGG-
CTTCTTTT-3′) with a 5′ end at nt 3305; D. dsx DNA templates were
obtained by linearization of pZMZ1-1 with Hind III (Zheng et al.,
1996); and the human β-globin minigene in plasmid pSP64-HβΔ6
linearized with Bam HI was originally purchased from Promega
(Madison, WI) and was described in our previous publication (Zheng
et al., 1999).
To generate various sizes of RNA transcripts fromHPV16 E6E7 DNA
templates for the RNA binding assays described in Fig. 7, various 5′
chimeric T7-HPV16 primers at different locations were combinedwith
various antisense 3′ primers in different positions for PCR ampliﬁca-
tion from pBR322-HPV16 DNA. The PCR DNA templates were then
subjected to in vitro run-off transcription assays for the production of
individual RNAs with desired regions. The positions and sizes of
individual templates used for in vitro run-off transcription are
reﬂected at the ends of each RNA described in Fig. 7A.
Capped, 32P-labeled run-off transcripts were synthesized from
each DNA template by in vitro run-off transcription using T7 RNA
polymerase in the presence of [α-32P]GTP (Zheng and Baker, 2000).
However, SP6 RNA polymerase was used to transcribe the human β-
globin transcript as suggested by Promega. All RNA transcripts were
gel-puriﬁed and quantiﬁed with a liquid scintillation counter (Beck-
man Instruments, Palo Alto, CA). The labeled transcripts were stored at
−80 °C until use.
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Splicing reactions were carried out in the presence of HeLa or 293
NE at 30 °C for 2 h. The detailed protocol for in vitro splicing and
calculation of the splicing efﬁciency have been described elsewhere
(Zheng and Baker, 2000). Splicing inhibition (%) by each protein was
calculated as [1− (a /b)]×100, where the a equals to the percentage of
splicing efﬁciency in the presence of a testing protein and the b equals
to the splicing efﬁciency in the absence of a testing protein. A splicing
gel in each ﬁgure is a representative of at least 2–3 separate
experiments.
Expression and puriﬁcation of GST fusion proteins
The individual viral gene constructs in pGEX-6P-1 expression
vectors described above were expressed as GST fusion proteins in E.
coli either in strain BL21(DE3)pLysS (Promega) or in BL21 Codon Plus
(DE3)-RP (Stratagene, La Jolla, CA). Codon Plus RP bacteria cells are
engineered to encode extra copies of speciﬁc tRNA genes that are rare
in E. coli, but common in humans. Overnight pre-cultures were
diluted 100-fold in fresh 2× YTA medium (yeast extract, 10 g/l;
tryptone, 16 g/l; sodium chloride, 5 g/l; pH 7.0) containing 100 μg/ml
ampicillin and were incubated at 37 °C until an OD600 of 0.6–0.8 was
reached. The expression of the fusion proteins was induced with
0.25–1.0 mM IPTG at 18–37 °C for 2–20 h (see details in Table 1). Cells
were collected by centrifugation and resuspended in 50 μl (for each
milliliter of the culture centrifuged) of ice-cold 1× PBS (140 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) in the presence
of 1% (v/v) Triton X-100 and Complete Mini EDTA-free Protease
Inhibitor Cocktail (1×, Cat.# 1836170, Roche, Indianapolis, IN).
Resuspended cells were aliquoted into a fresh Eppendorf tube and
stored at −20 °C until protein puriﬁcation. Bacteria cells were lysed in
the presence of 100 μg/ml lysozyme and 3–5 U DNase I by 10 cycles of
freeze/thaw, in combination with homogenization using a syringe.
Subsequently, cell debris was removed from the lysate by centrifuga-
tion at 13,000 rpm for 10 min. Finally 750–1500 μl of supernatant was
loaded onto a microspin column containing glutathione Sepharose 4B
beads (50 μl bed volume, Amersham Pharmacia) and incubated with
gentle rocking on a shaker for 20 min at room temperature. The
beads were then washed 6 times with 150 gel-volumes of ice-cold
PBS (1×). GST or recombinant fusion proteins were eluted at least 4
times from each column; each elution was performed by low speed
centrifugation (735 ×g) with 50 μl of 10 mM glutathione in the
presence of 1 mM DTT and Complete Mini EDTA-free Protease
Inhibitor Cocktail as described above. To remove the GST tag from
selected GST fusion proteins, a total of 50 μl of cleavage buffer
(50 mM Tris–HCl, 150 mM NaCl, 1 mM DTT, pH 7.0) and 4 U of
PreScission protease (Amersham Pharmacia) was applied to the
column after the last wash and before elution of the fusion proteins
from the column. The column was then incubated at 4 °C overnight.
The digested proteins without GST were eluted four times, each with
50 μl of cleavage buffer. All protein samples were analyzed using SDS-
PAGE gels stained with Coomassie Blue. The concentration of proteins
was measured either by UV absorbance at 280 nm or by comparing
the intensity of the band of the protein of interest to that of the
standard protein marker (5 μg) or BSA (2 μg). The intensity
comparison was used to calibrate the UV absorbance curve and
5 μg of puriﬁed GST fusions quantiﬁed from UV absorbance was
found to contain approximately 500 ng of an expected pure protein.
For our convenience, the concentration of GST fusion proteins
measured with UV is described in the text for all experiments.
All puriﬁed proteins were freshly prepared from 1.5 ml aliquots of
the transformed and induced bacteria suspension less than 2 weeks
after induction and were analyzed immediately in each experiment.
Occasionally, glycerol was added to individual protein preparation at a
ﬁnal concentration of 20% for a short storage at −80 °C.Protein pull-down assays and Western blotting
Each freshly expressed fusion protein or GST was ﬁrst immobilized
on glutathione Sepharose 4B beads and washed 7 times with 150 gel-
volumes of ice-cold PBS (1×) as described above. The protein-
immobilized beads was placed in a fresh microspin column (Amer-
sham Pharmacia) and washed once at 800 ×g for 5 min with 750 μl of
buffer A [PBS (1×) with a ﬁnal concentration of 1 mM each of EGTA,
EDTA, KF, Na3VO4, β-glycerophosphate, 1% (v/v) Triton X-100 and
Complete Mini EDTA-free Protease Inhibitor Cocktail (1 tablet/10 ml)
as described above]. Twenty microliters (7.5 μg/μl) of HeLa NE
(ProteinOne, College Park, MD) in 500 μl of buffer A was added to
the microspin column containing the protein-immobilized beads,
which was tumbled overnight at 4 °C. After washing the beads 7 times
with 750 μl of ice-cold buffer A, 50 or 120 μl of 4× SDS sample buffer,
depending on the individual protein were added to the beads, which
were then heated to 95 °C for 10 min. The protein samples were
resolved on a 4–12% SDS-PAGE gel, transferred onto a nitrocellulose
membrane, probed with a monoclonal anti-SR protein antibody
mAb104 followed by a horseradish peroxidase-conjugated goat anti-
mouse IgM (Sigma), and visualized using a SuperSignal West Pico
chemiluminescence detection system (Pierce Biotech, Rockford, IL).
Protein–RNA interaction and UV crosslinking
The same procedure was followed as described previously (Zheng
et al., 1997). Brieﬂy, each puriﬁed fusion protein (∼5 μg) was incubated
with 8 ng (∼2.8×105 cpm) of 32P-labeled RNA substrates in 4 μl of 5×
splicing buffer containing 3% polyvinyl alcohol, 2 mM ATP, 100 mM
creatine phosphate, and 25 mM HEPES (pH 7.9) in a total volume of
20 μl/well in an ice-cold, ﬂat-bottom 96-well plate. After 15 min
incubation on ice, heparin was added to each well at a ﬁnal
concentration of 0.5 mg/ml, and the reaction was immediately
subjected to UV irradiation (total 4800 mJ/cm2) in a UV Stratalinker
(Stratagene) on ice. The irradiated sample was mixed with RNase A
(20 μg) and RNase T1 (200 U), incubated for 30 min at 37 °C, and then
subjected to 10% or 4–12% SDS-PAGE gel electrophoresis. The cross-
linked RNA–protein resolved on the gel was captured using a
Molecular Dynamic PhosphorImager Storm 860 and analyzed with
Image-Quant software. The dried SDS-PAGE gel was then re-hydrated
overnight and stained with Coomassie Blue for protein sampling.
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